This HTML5 document contains 116 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/kegg-compound/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/pdb/
dctermshttp://purl.org/dc/terms/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/pubchem-compound/
n6http://linked.opendata.cz/resource/AHFS/
n13http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n18http://linked.opendata.cz/resource/drugbank/dosage/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/kegg-drug/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/pubchem-substance/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/drugbank/
n21http://bio2rdf.org/drugbank:
n30http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n25http://www.rxlist.com/cgi/generic/
n23http://linked.opendata.cz/resource/drugbank/patent/
n16http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n17http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n11http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n9http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/pharmgkb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00410/identifier/wikipedia/
n12http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00410
rdf:type
n3:Drug
n3:description
Mupirocin (pseudomonic acid A, or Bactroban or Centany) is an antibiotic originally isolated from Pseudomonas fluorescens. It is used topically, and is primarily effective against Gram-positive bacteria. Mupirocin is bacteriostatic at low concentrations and bactericidal at high concentrations. Mupirocin has a unique mechanism of action, which is selective binding to bacterial isoleucyl-tRNA synthetase, which halts the incorporation of isoleucine into bacterial proteins. Because this mechanism of action is not shared with any other antibiotic, mupirocin has few problems of antibiotic cross-resistance.
n3:dosage
n18:271B462F-363D-11E5-9242-09173F13E4C5 n18:271B4630-363D-11E5-9242-09173F13E4C5 n18:271B462C-363D-11E5-9242-09173F13E4C5 n18:271B462D-363D-11E5-9242-09173F13E4C5 n18:271B462E-363D-11E5-9242-09173F13E4C5
n3:group
approved investigational
n3:halfLife
20 to 40 minutes
n3:indication
For the treatment of <i>Staphylococci</i> nasal carriers.
n3:manufacturer
n13:271B4619-363D-11E5-9242-09173F13E4C5 n13:271B461A-363D-11E5-9242-09173F13E4C5 n13:271B461D-363D-11E5-9242-09173F13E4C5 n13:271B461B-363D-11E5-9242-09173F13E4C5 n13:271B461C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n16:DB00410 n21:DB00410
dcterms:title
Mupirocin
adms:identifier
n8:Mupirocin n9:PA164764568 n22:393914 n24:46505594 n26:C11758 n27:D01076 n28:DB00410 n29:446596 n30:0062-1610-01 n31:MRC
n3:mechanismOfAction
Mupirocin reversibly binds to bacterial isoleucyl-tRNA synthetase, an enzyme which promotes the conversion of isoleucine and tRNA to isoleucyl-tRNA. Prevention of this enzymes from functioning properly results in the inhibition of bacterial protein and RNA synthesis.
n3:packager
n13:271B460B-363D-11E5-9242-09173F13E4C5 n13:271B4617-363D-11E5-9242-09173F13E4C5 n13:271B4618-363D-11E5-9242-09173F13E4C5 n13:271B460E-363D-11E5-9242-09173F13E4C5 n13:271B460F-363D-11E5-9242-09173F13E4C5 n13:271B460C-363D-11E5-9242-09173F13E4C5 n13:271B460D-363D-11E5-9242-09173F13E4C5 n13:271B4615-363D-11E5-9242-09173F13E4C5 n13:271B4607-363D-11E5-9242-09173F13E4C5 n13:271B4616-363D-11E5-9242-09173F13E4C5 n13:271B4608-363D-11E5-9242-09173F13E4C5 n13:271B4613-363D-11E5-9242-09173F13E4C5 n13:271B4605-363D-11E5-9242-09173F13E4C5 n13:271B4614-363D-11E5-9242-09173F13E4C5 n13:271B4606-363D-11E5-9242-09173F13E4C5 n13:271B4611-363D-11E5-9242-09173F13E4C5 n13:271B4609-363D-11E5-9242-09173F13E4C5 n13:271B4612-363D-11E5-9242-09173F13E4C5 n13:271B460A-363D-11E5-9242-09173F13E4C5 n13:271B4610-363D-11E5-9242-09173F13E4C5 n13:271B4604-363D-11E5-9242-09173F13E4C5
n3:patent
n23:6013657
n3:routeOfElimination
Following the application of Centany (mupirocin ointment),2% to a 400 cm2 area on the back of 23 healthy volunteers once daily for 7 days, the mean (range) cumulative urinary excretion of monic acid over 24 hrs following the last administration was 1.25% (0.2% to 3.0%) of the administered dose of mupirocin.
n3:synonym
Pseudomonic acid Bactroban Centany Mupirocine Pseudomonic acid a Mupirocinum 9-[(E)-4-[(2S,3R,4R,5S)-3,4-dihydroxy-5-[[(2S,3S)-3- [(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl]methyl] oxan-2-yl]-3-methylbut-2-enoyl]oxynonanoic acid Mupirocina
n5:hasAHFSCode
n6:84-04-04
n3:proteinBinding
97%
n3:salt
n3:synthesisReference
Harvey Lee Zimmerman, "Pharmaceutical and veterinary compositions of mupirocin and methods for their preparation." U.S. Patent US6025389, issued January, 1988.
n19:hasConcept
n20:M0025454
foaf:page
n11:mupirocin-cream.html n25:mupi.htm
n3:IUPAC-Name
n4:271B4635-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B463B-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B463A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4637-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4638-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4639-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4633-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4634-363D-11E5-9242-09173F13E4C5 n4:271B4631-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4632-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n12:D06AX09 n12:R01AX06
n3:H-Bond-Acceptor-Count
n4:271B4641-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4642-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B463C-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B463D-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B463F-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B463E-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4640-363D-11E5-9242-09173F13E4C5
n3:absorption
No measurable systemic absorption
n3:affectedOrganism
Staphylococcus aureus Enteric bacteria and other eubacteria
n3:casRegistryNumber
12650-69-0
n3:category
n3:containedIn
n17:271B462B-363D-11E5-9242-09173F13E4C5 n17:271B4621-363D-11E5-9242-09173F13E4C5 n17:271B4622-363D-11E5-9242-09173F13E4C5 n17:271B461F-363D-11E5-9242-09173F13E4C5 n17:271B4620-363D-11E5-9242-09173F13E4C5 n17:271B461E-363D-11E5-9242-09173F13E4C5 n17:271B4629-363D-11E5-9242-09173F13E4C5 n17:271B462A-363D-11E5-9242-09173F13E4C5 n17:271B4627-363D-11E5-9242-09173F13E4C5 n17:271B4628-363D-11E5-9242-09173F13E4C5 n17:271B4625-363D-11E5-9242-09173F13E4C5 n17:271B4626-363D-11E5-9242-09173F13E4C5 n17:271B4623-363D-11E5-9242-09173F13E4C5 n17:271B4624-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4647-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4649-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B464A-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B464B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4646-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4645-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4648-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4636-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4643-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4644-363D-11E5-9242-09173F13E4C5